Enanta Pharmaceuticals Stock Prediction and Forecast [ENTA]

AI-generated source summary

The video provides an analysis of Enanta Pharmaceuticals stock, updated as of September 28, 2025. Stock score data from September 26, 2025, assigned a hold or accumulate rank to Enanta Pharmaceuticals with a score of -0.108. Current assessment reveals the stock is positioned within a rising trend in the short term. Potential change of approximately 12.4% may be seen in the next three months, returns between 2.71% and 31.62%. The 12-month analysis predicts a projected change of -20.6%. The stock's price could fluctuate between negative 67.90% and negative 10.35% over the coming year. Trading volume increased on the last day. Fibonacci and Accumulated Volume support and resistance levels are given, with the support at $7.81 and resistance at $8.39. It has a weekly volatility of 7.31%. Capps Kathleen bought and sold 16115 shares in the company. It has a P/E ratio of -1.83 with a suggested stop-loss at $7.57.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   27 Sept 2025, 03:26 UTC

   The analyst published the original source item.

2. First prediction resolved

   29 Sept 2025, 13:30 UTC

   The first evaluable outcome in this case reached a terminal result.

3. Case evaluation completed

   29 Sept 2025, 13:30 UTC

   All evaluable predictions in this case reached terminal outcomes.

4. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

5. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

6. Outcome tracking started

   02 Jul 2026, 02:11 UTC

   Tahlil Plus began monitoring the extracted predictions.